HKEX Stock Code: 01093English|繁體|简体
Financial Summary
  For the year ended 31 December
  2016
RMB'000
(Restated)
(note)
2017
RMB'000
(Restated)
(note)
2018
RMB'000
(Restated)
(note)
2019
RMB'000
 
(note)
2020
RMB'000
 
(note)
Results          
Revenue 10,575,530 13,386,479 17,716,540 22,103,192 24,942,204
Cost of sales (5,181,498) (5,303,764) (5,979,187) (6,192,211) (6,256,882)
           
Gross profit 5,394,032 8,082,715 11,737,353 15,910,981 18,685,322
Other income 82,902 103,366 139,742 243,783 264,736
Other gains or losses (6,904) (50,953) 155,195 48,450 376,816
Selling and distribution expenses (2,383,877) (3,780,688) (6,184,505) (8,712,083) (9,377,620)
Administrative expenses (475,536) (555,581) (656,597) (748,509) (945,713)
Research and development expenses (344,685) (703,458) (1,342,101) (2,000,426) (2,889,837)
Other expenses (623) (79,083) (26,125) (142,015) (57,036)
           
Operating profit 2,265,309 3,016,318 3,822,962 4,600,181 6,056,668
Finance costs (35,663) (23,182) (74,337) (32,426) (12,232)
Share of results of          
   — an asssociate (20,917)
   — a joint venture 23,563 8,892 43,554 58,407 34,449
Gain on deemed disposal of partial interest in an associate 37,192
Gain on disposal of a subsidiary 314,901
Loss on deemed disposal of a subsidiary (19,038)
           
Profit before taxes 2,253,209 3,002,028 3,792,179 4,626,162 6,391,023
Income tax expense (446,401) (594,252) (733,760) (892,810) (1,162,013)
           
Profit for the year 1,806,808 2,407,776 3,058,419 3,733,352 5,229,010
           
Profit for the year attributable to:          
   Owners of the company 1,796,226 2,399,484 3,080,802 3,714,106 5,159,655
   Non-controlling interests 10,582 8,292 (22,383) 19,246 69,355
           
  1,806,808 2,407,776 3,058,419 3,733,352 5,229,010
           
  RMB cents
(Restated)
RMB cents
(Restated)
RMB cents
(Restated)
RMB cents
(Restated)
RMB cents
Earnings per share          
   — basic 30.14 39.40 49.36 31.07 43.16
           
   — diluted 29.93 39.39 N/A 31.07 43.16



  As at 31 December
  2016
RMB'000
(Restated)
2017
RMB'000
(Restated)
2018
RMB'000
(Restated)
2019
RMB'000
 
2020
RMB'000
 
Assets and liabilities          
Total assets 13,210,366 17,988,805 23,216,837 26,318,322 30,070,206
Total liabilities (4,089,133) (5,129,097) (7,687,237) (6,800,157) (6,969,133)
         
Net assets 9,121,233 12,859,708 15,529,600 19,518,165 23,101,073
         
Equity attributable to owners of the Company 9,046,325 12,788,655 15,052,260 18,461,723 22,332,288
Non-controlling interests 74,908 71,053 477,340 1,056,442 768,785
         
Total equity 9,121,233 12,859,708 15,529,600 19,518,165 23,101,073
Note: Other gains or losses and research and development expenses were reclassified from other income, administrative expense and other expenses in the consolidated financial statements so as to conform with the current year presentation.
© Copyright 2021 CSPC Pharmaceutical Group Limited. All Rights Reserved.